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Cardiac myxomas are benign mesenchymal tumors that can present as components of the human autosomal dominant disorder Carney complex. Syndromic
cardiac myxomas are associated with spotty pigmentation of the skin and
endocrinopathy. Our linkage analysis mapped a Carney complex gene defect to
chromosome 17q24. We now demonstrate that the PRKAR1α gene encoding the
R1α regulatory subunit of cAMP-dependent protein kinase A (PKA) maps to
this chromosome 17q24 locus. Furthermore, we show that PRKAR1α frameshift
mutations in three unrelated families result in haploinsufficiency of R1α and
cause Carney complex. We did not detect any truncated R1α protein encoded
by mutant PRKAR1α. Although cardiac tumorigenesis may require a second
somatic mutation, DNA and protein analyses of an atrial myxoma resected from
a Carney complex patient with a PRKAR1α deletion revealed that the myxoma
cells retain both the wild-type and the mutant PRKAR1α alleles and that wildtype R1α protein is stably expressed. However, in this atrial myxoma, we did
observe a reversal of the ratio of R1α to R2β regulatory subunit protein, which
may contribute to tumorigenesis. Further investigation will elucidate the cellspecific effects of PRKAR1α haploinsufficiency on PKA activity and the role of
PKA in cardiac growth and differentiation.
This article may have been published online in advance of the print edition. The date of publication is available from the JCI website, http://www.jci.org.
J. Clin. Invest. 106:R31–R38 (2000).

Introduction
Cardiac myxomas are benign neoplasms that occur in 7 per 10,000 individuals (1). These slowly proliferating
lesions arise from subendocardial
pluripotent primitive mesenchymal
cells, which can differentiate within
myxomas along a variety of lineages
including epithelial, hematopoietic,
and muscular (2, 3). Morbidity and
mortality from cardiac myxomas are
the result of embolic stroke, heart failure due to intracardiac obstruction,

and rheumatologic symptoms attributed (4) to myxoma-mediated production of IL-6. Seven percent of cardiac
myxomas (1) are components of a
familial autosomal dominant syndrome (Figure 1) that has been variably
referred to as LAMB (lentigines, atrial
myxoma, mucocutaneous myxoma,
blue nevi) and NAME (nevi, atrial myxoma, myxoid neurofibromata, ephelides) and more recently as Carney complex (OMIM #160980, ref. 5; and ref. 6).
In Carney complex, autosomal domiThe Journal of Clinical Investigation
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nant cardiac myxomas are associated
with spotty pigmentation of the skin
and nonneoplastic hyperfunctioning
endocrine states, e.g., primary pigmented nodular adrenocortical hyperplasia.
Individuals affected with Carney complex may have extracardiac (most often
cutaneous) myxomas, as well as a variety of other benign neoplasms including schwannomas, pituitary adenomas,
thyroid adenomas, and breast fibroadenomas. Cardiac myxomas of Carney
complex are histologically indistinguishable from more common sporadic cardiac myxomas and, like the latter, most often arise in the left atrium at
the fossa ovalis (7). However, unlike
sporadic cardiac myxomas, which most
often occur as isolated single lesions in
middle-aged women and which are
usually amenable to surgical resection,
syndromic cardiac myxomas exhibit no
age or sex preference and may present
as multiple concurrent lesions in any
cardiac chamber. Affected individuals
may have multiple recurrences at any
cardiac location despite adequate surgical margins (7).
Clinical evaluation and genetic linkage analysis of families affected by Carney complex (8, 9) suggested two
human chromosomal loci for disease
genes: chromosome 2p16 and chromosome 17q24. Linkage to the chromosome 17q24 locus (CAR) was
R31

observed in five families affected by
Carney complex (8). We have now
refined the CAR interval and used a
positional cloning strategy to demonstrate that familial cardiac myxomas
and Carney complex are caused by
mutations in the gene (PRKAR1α)
encoding the R1α regulatory subunit
of cAMP-dependent protein kinase A
(PKA) on chromosome 17q24. We further propose that PRKAR1α acts as a
tumor suppressor gene to regulate cell
proliferation within the human heart.

These oligonucleotides were also used
to amplify a GNAS13 gene segment
from human genomic DNA. This
product was random hexamer–radiolabeled and used as a probe to screen
membrane arrays of the Roswell Park
Cancer Institute human genomic BAC
library. BAC and PAC DNA was prepared with the QIAGEN Large Construct kit (QIAGEN Inc.) and was
sequenced directly with oligonucleotides randomly designed from
GNAS13 coding sequence on an ABI
377 sequencer (Perkin-Elmer Inc.).
Primers were designed as follows from
intronic sequence flanking exons 2, 3,
and 4:

Methods
Clinical evaluation. Informed consent
was obtained from all participants in
accordance with the Weill Medical
College of Cornell University Committee on Human Rights in Research.
All family members were evaluated by
a thorough history and physical exam
without knowledge of genotype status.
If there was any evidence of dermatologic, cardiac, or endocrine disease
suggestive of Carney complex, patients
were further evaluated by electrocardiography, transthoracic echocardiography, and serum chemistry.
Genetic analyses. Peripheral blood was
obtained from each family member,
and lymphoblastoid lines were established by transformation with the
Epstein-Barr virus (8). Genomic DNA
and RNA were isolated from peripheral lymphocytes, lymphoblasts, or
tumor cells with QIAamp columns
(QIAGEN Inc., Valencia, California,
USA). Polymorphic short tandem
repeats (STRs) were amplified by PCR
with published nucleotide primer
sequences (10), analyzed on denaturing polyacrylamide gels (8), and visualized by autoradiography or on an
ABI 377 sequencer (Perkin-Elmer Inc.,
Norwalk, Connecticut, USA). Cytogenetic analysis of tumor and lymphocyte samples was performed as previously described (11).
Cloning and sequence analysis of
(5′GNAS13.
Oligonucleotides

Exon 2: 5′-GAGTCAGTTCGCTGGTTCC-3′
/ 5′-TGCCCTTAACCCCGGCCCCATTC-3′
Exon 3: 5′-AAGGTTTGTCTAGGTTAATTC-3′ / 5′-TAGCCTTTCAGTCTGTTCCTCCA-3′
Exon 4: 5′-GAGTCAGTTCGCTGGTTCC-3′
/ 5′-TGCCCTTAACCCCGGCCCCATTC-3′
Exon 5 was amplified in two overlapping
segments using primer pairs:
5′-AGGCATGACCACCATGTCTGACCA-3′
/ 5′-GATTGGTCAGTCGATCTTCCA-3′ 5′GTTTCGACAGTGTGACATCAATAC-3′ /
5′-TCTAATTCTGGTTGTAAACTGCTA-3′

CTATTCTGCATGACAACCTGAAGC-3′ /
5′-TCTAATTCTGGTTGTAAACTGCTA-3′)

corresponding to the 3′ portion of the
GNAS13 gene (12), including untranslated sequence, were used to screen, by
PCR, arrayed pools of the Roswell Park
Cancer Institute (Buffalo, New York,
USA) human genomic PAC library.
R32

Each exon was PCR-amplified with
the appropriate primer pair from
human genomic DNA samples with
reaction conditions as follows: [94°C ×
20 s, 57°C × 30 s, 72°C × 45 s] × 35
cycles. In all cases except exon 2 amplification, standard PCR reagents were
used with AmpliTaq Gold (PerkinElmer Inc.). Exon 2 was amplified with
the QIAGEN Taq DNA Polymerase Kit
(QIAGEN Inc.). Amplified products
were sequenced in both directions on
an ABI 377 automated sequencer using
BigDye Terminator Cycle Sequencing
reagents (Perkin-Elmer Inc.).
PRKAR1α sequence analysis. Oligonucleotides (as below) were designed based
on intronic sequence flanking each
PRKAR1α exon (3–11) and were used to
PCR-amplify them from human genomic DNA samples. PCR conditions were
[94°C × 20 s, 57°C × 30 s, 72°C × 45 s] ×
35 cycles with standard PCR reagents
and AmpliTaq Gold (Perkin-Elmer Inc.).
Exon 3: 5′-GAATTGGTGTTTTCCTCTTAACTT-3′ / 5′-TATGATTCATTCATCAAAGGAGAC-3′
Exon 4: 5′-AATGTTTTTGGTTTATGGAATTGT-3′ / 5′-CACACCCTTACTTGAAAA-
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ATAGTG-3′
Exon 5: 5′-GACAGTCTGGGGTCTTTAATTCTA-3′ / 5′-TCAAAGAGGAAAACAAACTTCAAT-3′
Exon 6: 5′-TTTCTTTAATTTGGAATATGCTTC-3′ / 5′-ATCTGACATACAAGGGATGTAATG-3′
Exon 7: 5′-TTTTTAAAACAAAGTTCAGGATTG-3′ / 5′-CTAAATCACACTCTCAAACACCAT-3′
Exon 8: 5′-ATTATTCCATAGCATTATGTGGTG-3′ / 5′-AGTCACAGAGGAAATAACTGTGAA-3′
Exon 9: 5′-GGCTATTTGTTGAATCTCTTTAT-3′ / 5′-TGAGTTCTTTACCTCTAAAATTCAA-3′
Exon 10: 5′-TTGTTTAGCTTTTTGG GATTTTA-3′ / 5’GGAGAAGACAAAA TATGGAAGAC-3′
Exon 11: 5′-TATTGTCTTCTTTCTCAGAAGTGC-3′ / 5′-GTGCAATAAAAGCAACTTTCAATA-3′

Exons 1 and 2 were amplified by RTPCR from patient lymphocyte or lymphoblast RNA samples with the
Access RT-PCR kit (Promega Corp.,
Madison, Wisconsin, USA) and
primers:
5′-GCTGGGAGCAAAGCGCTGAGGGA-3′
/ 5′-TGTAGACCTCAGCGCTGATAGC-3′

Amplified products were sequenced
in both directions on an ABI 377 automated sequencer using BigDye Terminator Cycle Sequencing reagents
(Perkin-Elmer Inc.). Two novel STRs,
an AG28 dinucleotide repeat and an
ATT11 trinucleotide repeat, were noted
in the PRKAR1α 5´ untranslated
region and 21 kb 3′ to the gene, respectively. PCR primers used to amplify
using these repeats for genotyping
studies were:
AG: 5′-CTGCAGGAAGAGGGAGAAATGGGAA-3′ / 5′-AGAAGTTAAGTGACTTGCCCATGGC-3′
ATT: 5′-TTTCAGCCTCAGTATCTTTATTTG-3′ / 5′-ACCTAAAGTCTTTCTGCCAGTTAT-3′

Western blot analysis. Lymphoblast and
tumor samples were solubilized in 2%
SDS. Equivalent protein concentrations of lysate were electrophoresed on
10% acrylamide denaturing gels and
transferred to PVDF membrane. Western blotting was performed with antiactin (Sigma Chemical Co., St. Louis,
Missouri, USA) and with primary
mAb’s to the R1α and R2β PKA subunits (Becton Dickinson Transduction

Laboratories, Lexington, Kentucky,
USA). Antigenic epitopes in the PKA
regulatory subunits are in the NH2-terminal hinge region (13), and positive
controls supplied by Becton Dickinson
Transduction Laboratories were rat
cerebrum lysate (R1α) and human aortic endothelial lysate (R2β). Bound primary antibody was detected by ECL
(Amersham Pharmacia Biotech, Piscataway, New Jersey, USA). Densitometry
was performed with a Fluor-S imaging
system and MultiAnalyst software
(Bio-Rad Laboratories Inc., Hercules,
California, USA). An equivalent
amount of total cellular protein for
lymphoblast samples was loaded on
each gel, based on actin expression. As
estimated relative to actin expression,
the amount of myxoma lysate cellular
protein loaded was 10% of lymphoblast
lysate cellular protein.

Results
Genetic and physical mapping of the CAR
locus. Our previous analyses demonstrated that the Carney complex disease
gene is located in the 17-cM interval
between D17S807 and D17S785. Analysis of high-density genetic and physical
maps (10, 12) of this locus (Figure 2)
permitted the fine ordering of ten additional microsatellite polymorphisms
(Figure 2, Table 1) within this interval,
which were used to genotype families
YA and YB. Haplotype analysis revealed
recombination events between the Carney complex disease gene and D17S1882
and D17S929 at the centromeric and
telomeric ends, respectively, of the CAR
locus. Thus, these genetic analyses
refined the CAR locus and established a
minimal genetic interval of about 12 cM
between D17S1882 and D17S929 for the
CAR locus.
Exclusion of GNAS13. Computerized
analysis of the Human Genome Project/GenBank database (12) revealed
that the D17S2016 sequence-tagged
site (STS) was included within the centromeric portion of the CAR locus.
BLAST analysis of this STS demonstrated that the sequence corresponded to the coding sequence of the
GNAS13 gene (GenBank accession no.
L22075) encoding the GTP-binding
protein, Gα13. Mutations in another
GTP-binding protein involved in intracellular signal transduction, Gsα,

cause McCune-Albright syndrome,
which shares several phenotypic features with Carney complex, including
abnormal skin pigmentation and
endocrinopathy (5), but Gsα mutations are not found in Carney complex
patients (14). Given the homologies
between Gα13 and Gsα and the chromosomal location of the GNAS13
gene, we searched for mutations in the
GNAS13 gene in five unrelated Carney
complex patients.
We screened the Roswell Park Cancer Institute BAC and PAC human
genomic DNA libraries and identified
six BAC (472J20, 484A6, 583F2,
489G5, 657B12, 752A23) and four
PAC
(704J11556,
704K19308,
704A09613, 704A10613) clones for
GNAS13. Comparison of BAC/PAC
sequences with GNAS13 cDNA
sequence established the genomic
structure of the human GNAS13 gene:

5 exons with an open reading frame
beginning in exon 2. Exons 2–5
(GNAS13 coding sequence) were
amplified from patient DNA samples
and subjected to automated sequencing. Although a GGC7 trinucleotide
STR within the 5′ untranslated
sequence in exon 2 of GNAS13 (3 bp
5′ to the translation start site) was
found to be polymorphic, no mutations were founding within the
GNAS13 coding sequence.
Identification of PRKAR1α mutations.
Interrogation of the Human Genome
Project databases further revealed that
the PRKAR1α gene (accession no.
NM002374) encoding the R1α regulatory subunit of cAMP-dependent PKA
was also included within the CAR
locus minimal interval (Figure 2).
PRKAR1α had previously been
mapped (as the Tissue-Specific Extinguisher 1 [TSE1] locus) to chromo-

Figure 1
Pedigree of family YF and cardiac myxoma in a proband. The subject number and disease
status of each family member analyzed are indicated. Squares denote male family members,
and circles females. Affected and unaffected individuals are represented by closed and open
symbols, respectively. Carney complex is transmitted in an autosomal dominant fashion.
Transesophageal echocardiography of individual I-1 revealed an unusual posterior mass
(arrow) in the right atrium (RA) below the eustachian valve (EV). Pathologic analysis at surgery revealed that the mass was a cardiac myxoma.
The Journal of Clinical Investigation
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some 17q23-q24 by somatic cell
hybrid analysis (15, 16). Additionally,
we noted that the 155-kb human
genomic BAC clone RP11-62F10
(accession no. AC005799.1) contained
sequences corresponding to both
PRKAR1α and the anonymous STR
D17S789, which exhibited no recombination with the Carney complex disease gene in the families that we had
studied. Therefore, the PRKAR1α
chromosomal location, the known
role of PKA in signal transduction and
cell growth, and the ubiquitous expression pattern of the R1α subunit
(16–18) all suggested that PRKAR1α
was a candidate disease gene for Carney complex.
The coding sequence of PRKAR1α is
1.146 kb in length. Comparison of
the genomic sequence derived from
BAC RP1162F10 with PRKAR1α
cDNA sequence elucidated the
intron-exon boundaries and showed
that the gene was comprised of 11
exons (Figure 3), not 10 as previously
reported (19). However, no novel
genomic sequence was available in the
Human Genome Project database
corresponding to exons 1 and 2 of the
PRKAR1α gene to compare with the
previously described genomic structure (accession no. Y07641). Analysis
of the genomic sequence of a
PRKAR1α pseudogene contained
within BAC clone RP4-621B10 (ref.
19; accession no. AL13883), which
maps to chromosome 1 and begins
with sequence 5′ to the open reading
frame, raised the possibility that the
proposed boundary (19) between
exons 1 and 2 might be imprecise.
To analyze the coding sequence of
the PRKAR1α gene for mutations that
might cause Carney complex, we
designed PCR primers from the intron
sequence flanking exons 3–11 and
amplified these exons from human
genomic DNA samples. Because of
ambiguity about the genomic organization of PRKAR1α exons 1 and 2, we
designed oligonucleotides based on
coding sequence from exon 3 and on 5′
untranslated sequence within exon 1
to amplify, via RT-PCR, exons 1 and 2
from lymphocyte/lymphoblast RNA
samples. PRKAR1α exons 1–11 amplified from five Carney complex unrelated probands were then subjected to
R34

sequence analysis. Two probands were
from families that had been linked to
chromosome 17q24 (families YA and
YB), and the others (YE, YF, and SY2)
were from families that were too small
to definitively establish linkage to any
chromosomal locus. Clinical features
of families YA and YB have been previously described (8). Probands from the
other three families all exhibit spotty
pigmentation of the skin and have had
cardiac myxomas.
We observed heterozygous PRKAR1α
gene mutations (Figures 3 and 4) in
three Carney complex probands,
including the two probands from chromosome 17q24–linked families (YA
and YB). Bidirectional sequence analysis demonstrated the presence of a 1-bp
deletion (G) of nucleotide 710 at
Gly208 in affected individuals but not
unaffected individuals in family YA
with a consequent frameshift and premature stop 13 codons later. A 2-bp
deletion (TC) of nucleotides 845–846
at Val253 was observed in affected individuals but not unaffected individuals
from family YB with a consequent
frameshift and premature stop 15
codons later. A 2-bp deletion (TG) of

nucleotides 576–577 at Thr163 was
present in all affected individuals but
not in unaffected individuals in family
YF with a resultant frameshift leading
to a premature stop 6 codons later.
Mutations (∆FSterGly208 in family
YA, ∆FSterVal253 in family YB,
∆FSterThr163 in family YF) were confirmed by sense and antisense sequence
analysis and by gel electrophoresis of
PCR products to demonstrate the different lengths of the alleles. None of
these sequence variants was observed
in 100 normal unrelated chromosomes. We also observed a single base
pair thymine insertion in a poly-T tract
in intron 3 that is 9 nucleotides 5′ to
the exon 4 splice acceptor site. This
insertion was a common polymorphism that was present in 50% of individuals genotyped.
PRKAR1α analysis in a cardiac myxoma. The frameshift PRKAR1α mutations observed in families YA, YB, and
YF would all yield truncated protein
products lacking the cAMP-binding
domains (Figure 3) if the mutant alleles were transcribed and translated.
Alternatively, these mutant alleles
might be null alleles due to degrada-

Figure 2
Ideogram of chromosome 17 with Giemsa banding pattern showing localization of the Carney complex locus and the PRKAR1α gene. Positive bands are black and the pericentromeric
region is gray. Numbers indicate cytogenetic designations for bands. The genetic map locations of polymorphic loci analyzed from 17q are given. One centimorgan (cM) is indicated.
Linkage data suggested that the gene responsible for Carney complex is located in the 12-cM
interval between D17S1882 and D17S929 (CAR). Both GNAS13 and PRKAR1α map cytogenetically to chromosome 17q23-q24.
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in the R1α:R2β ratio secondary to
decreased R1α expression consistent
with PRKAR1α haploinsufficiency.
However, in the tumor sample there
was a reversal in the R1α:R2β ratio
that may relate to further decreased
R1α and/or increased R2β (Figure 5).

Figure 3
Three frameshift mutations in PRKAR1α that cause Carney complex. A schematic representation of PRKAR1α cDNA shows exons 1–11. Regions that encode functional domains
(dimerization domain, antigenic sites, hinge/pseudophosphorylation site, cAMP-binding
domains A and B) of R1α are denoted (13). Location of the PRKAR1α deletion mutations
∆FSterGly208 in family YA, ∆FSterVal253 in family YB, and ∆FSterThr163 in family YF are
shown. Mutations are denoted by ∆FSter to indicate a deletion with resultant frameshift and
premature stop codon, and by the first amino acid residue affected by the deletion.

tion of the mutant mRNA via nonsense-mediated decay (20). To distinguish between these possibilities,
expression of the R1α protein was
determined with specific antibody to
the NH2-terminus of R1α by Western
blot (Figure 5) of lymphoblasts derived
from a normal individual, lymphoblasts derived from an affected
individual (family YA, IV-1 with the
Gly208 deletion/frameshift mutation
described above), and a left atrial myxoma from this affected individual.
Only full-length R1α protein was present in all three samples without any
evidence of truncated product. Densitometry showed that the amount of
R1α protein in Carney complex lymphocytes was 60% less than that in
normal lymphocytes, consistent with
haploinsufficiency of PRKAR1α in
Carney complex. Full-length R1α was
also present in the atrial myxoma sample, suggesting that the wild-type allele
is preserved in the tumor. Cytogenetic
analysis of this atrial myxoma revealed
a normal 46,XX karyotype and failed
to demonstrate any abnormalities at
chromosome 17q23-24. Genotyping
with STR D17S789, which is closely
genetically and physically linked to the
PRKAR1α gene as described above, as
well as with an ATT trinucleotide
repeat 21 kb 3′ to the PRKAR1α coding sequence demonstrated no loss of
heterozygosity at this locus. (Genotyping with an AG dinucleotide repeat in
the 5′ untranslated PRKAR1α
sequence was uninformative.) Sequence analysis of PRKAR1α exon 7
shows that both the wild-type and

deleted mutant alleles are present in
this tumor. Finally, to date, we have
not detected any additional sequence
variants in PRKAR1α amplified from
this atrial myxoma. Densitometry of
Western blot analysis (Figure 5) of the
R2β regulatory subunit in the same
samples (normal lymphoblasts, Carney complex lymphoblasts, and atrial
myxoma) analyzed for R1α protein
expression demonstrated that R2β
expression was similar in normal and
affected lymphocytes, with a decrease

Discussion
We have demonstrated that mutations
in the PRKAR1α gene encoding the
R1α regulatory subunit cause familial
cardiac myxomas in autosomal dominant Carney complex. Individuals at
risk for cardiac myxomas who are
affected by Carney complex develop
disease based on PRKAR1α haploinsufficiency secondary to heterozygous
constitutional frameshift mutation of
PRKAR1α that results in a nonexpressed allele. Moreover, PRKAR1α
acts as a tumor suppressor gene in the
heart and other tissues, presumably by
regulation of PKA activity. PRKAR1α
function as a tumor suppressor gene is
consistent with findings (21) demonstrating that PRKAR1α accounts for
tissue-specific inhibition of gene transcription at the TSE1 locus on chromosome 17q24. Haploinsufficiency of
another kinase, STK11, followed by

Table 1
Haplotype analysis of individuals in families affected by Carney complex

Designations of individuals who are affected by Carney complex are in bold. Microsatellites from chromosome 17q are ordered from centromere to telomere. Recombination events between Carney complex
disease gene and microsatellites are shown in black. Individuals who are concordant are shown in white,
and uninformative analyses are shown in gray. The boxed region shows the minimal chromosome 17q24
interval (12 cM between D17S1882 and D17S929) for the Carney complex disease gene in which there is
no evidence of recombination.

The Journal of Clinical Investigation

|

Volume 106

R35

Figure 4
Mutational analysis of PRKAR1α in Carney complex families YA, YB, and YF. Automated
sequence analyses of wild-type and mutant exons 7, 8, and 5 amplified from normal and
affected individuals in families YA, YB, and YF, respectively, are shown. Sequence of the sense
strand is shown for family YA, and the antisense strand for families YB and YF. A heterozygous 1-bp deletion is noted in family YA, and 2-bp deletions in families YB and YF (arrows;
deleted bases are underlined). These mutations all result in a frameshift with consequent
premature stop codons.

somatic mutation, causes the phenotypically related Peutz-Jeghers syndrome, characterized by benign neoplasms and spotty pigmentation of
the skin (22). Similarly, constitutional
mutation of PRKAR1α followed by
somatic mutation of PRKAR1α or
other melanocyte genes likely accounts
for the spotty skin pigmentation in
Carney complex. We have not observed
a second acquired somatic mutation
of the PRKAR1α wild-type allele in the
tumor analyzed here, but a “two-hit”
mechanism of tumorigenesis (23)
remains possible for other syndromic
and nonsyndromic cardiac myxomas.
Although our Western blot analyses
detected no mutant, truncated R1α
protein in a cardiac myxoma, failure to
recognize truncated protein could be
due to low levels of protein or to conformational abnormalities with consequent loss of antigenicity. Thus, a
dominant-negative contribution of a
mutant protein remains a formal possibility. Our findings do show that if a
second “hit” is necessary for cardiac
tumorigenesis, the acquired mutation
is not required to occur in PRKAR1α.
The diverse signal transduction proteins that interact with R1α and
cAMP-dependent PKA, as well as other
PKA subunits, are candidates to be
studied for somatic mutation in these
tumors. Such a two-gene model of
tumorigenesis is similar to that
observed in murine neurofibromatosis
models, which require null alleles in
R36

the NF1 tumor suppressor gene as well
as p53 for tumorigenesis (24, 25).
Loss of the R1α regulatory subunit
promotes cell proliferation and
growth of benign tumors in multiple
tissues. The cell biological consequences of the genetic abnormalities
in R1α are likely mediated via changes
in PKA activity. The PKA holoenzyme
is a tetramer comprised of two catalytic subunits and two regulatory subunits. Genes for four regulatory subunits have been identified — R1α, R1β,
R2α, and R2β (3, 18) — which differ in
their tissue-specific expression patterns (3, 26). In its tetrameric form,
PKA is inactive. Upon binding of
cAMP to the regulatory subunits, the
regulatory subunit dimer undergoes a

conformational change and dissociates from the catalytic subunits; the
free catalytic subunits are enzymatically active. Activity of cAMP-dependent PKA can either inhibit or stimulate
cell proliferation depending on the cell
type (18, 26–28). PKA activity in any
given cell type is dependent not only
upon the concentration of free catalytic subunit but also upon the cell
type–specific ratio of regulatory subunits (3). R1:R2 is modulated not only
at the gene expression level (18, 19, 29)
but at the protein level by a wide array
of different cell type–specific binding
proteins for the regulatory subunits (A
kinase–anchoring proteins, or AKAPs)
(26–31). Changes in one regulatory
subunit concentration may incompletely compensate for changes in
another. For instance, knockout of
R1β or R2β in mice leads to a partial
increase in R1α, but overall PKA activity is still decreased (26, 29). McKnight
and colleagues (26, 29) have hypothesized that maintenance of adequate
R1α is a critical intracellular protective
mechanism against unregulated catalytic subunit activity.
Hyperendocrine states, benign
endocrine neoplasms (e.g., pituitary
and thyroid adenomas), and the cutaneous spotty pigmentation of the skin
seen in Carney complex are all likely
related to increased PKA activity. Elevated PKA activity can be caused by
increased free active catalytic subunit
in the absence of the regulatory/inhibitory R1α regulatory
subunit. For instance, constitutive

Figure 5
Western blot analysis of R1α and R2β in normal lymphoblasts, Carney complex lymphoblasts, and Carney complex cardiac myxoma. (a) Positive controls for antibodies to R1α
and R2β were electrophoresed and Western blotted as described in Methods. (b, c) Protein
lysates of lymphoblasts from (b) a normal individual and (c) an individual affected by Carney complex (family YA, IV-1) were electrophoresed and analyzed. Densitometry revealed
similar levels of R2β protein in the two samples but a 60% decrease in R1α levels. (d) R1α
and R2β were analyzed in lysate from a left atrial myxoma resected from individual IV-1 in
family YA. Densitometry was used to determine R1α and R2β expression in all samples, and
the ratio of R1α:R2β was calculated. A reversal of the R1α:R2β ratio is observed in the tumor
sample compared with affected and unaffected lymphocytes.
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activation of cAMP-dependent PKA
activity produces unregulated growth
of autonomous hyperfunctioning
human thyrocytes, and mutations in
Gsα, which yield elevated cAMP levels
and elevated PKA activity, cause
growth hormone–secreting pituitary
adenomas and thyroid adenomas (32,
33). Thus, loss of the R1α regulatory
subunit and increased PKA activity
may result in thyroid adenomas as
seen in individual I-1 in family YB.
Similarly, PKA activity is required for
tyrosine hydroxylase (TH) activity that
contributes both to catecholamine
synthesis and biosynthesis of melanin
skin pigmentation (34). PKA deficiency decreases TH activity not only due
to loss of TH phosphorylation but
also because PKA is required for transcriptional regulation of TH gene
expression (34).
In nonendocrine cell types, loss of
PKA activity may be associated with
increased cell proliferation (18, 26, 28).
For instance, Svenningsen and Kanje
(28) demonstrated that cAMP-dependent PKA inhibits Schwann cell proliferation, and pharmacologic inhibition
of PKA promotes Schwann cell
growth. Thus, benign schwannomas
seen in Carney complex patients,
including individual III-10 from family YA, may be a consequence of
decreased Schwann cell PKA activity.
In these cells, loss of PRKAR1α may
result in decreased PKA activity
through regulatory isoform switching,
as in the atrial myxoma studied here,
or through altered intracellular PKA
binding and sequestration by
Schwann cell–specific AKAPs that
have not yet been identified.
The cellular mechanism by which
loss of PRKAR1α modifies PKA activity in the heart and produces cardiac
myxomas remains uncertain. Cardiac
myxomas arise from rare pluripotent
subendocardial mesenchymal stem
cells (2–3). These unusual cardiac cells
have not been isolated or cultured (35),
and the effects of PKA on their biology
are unexplored. Rheumatologic symptoms in patients with cardiac myxomas are often attributed to elevated
serum IL-6, whose synthesis is PKAdependent (36). Normal cardiac structure and function require physiologic
expression of the CREB transcription

factor (37), which is at least partially
regulated by PKA-dependent phosphorylation. Both the Cα catalytic
subunit and the R1α regulatory subunit are expressed in the developing
heart (16–18). Imaizumi-Scherrer et al.
(17) concluded that there were low levels of R1α mRNA throughout the E16
mouse heart. However, close examination of their in situ hybridization data
(17) suggests that there may be focal
increase of R1α expression at the
interatrial septum, where most cardiac
myxomas, nonsyndromic and syndromic, arise.
We have previously observed (38)
that lipomatous hypertrophy of the
interatrial septum is common in
young adults affected by Carney complex. Knockout mice homozygousnull for the R2β subunit exhibit a partial compensatory increase in R1α
expression but an overall decrease in
PKA activity, and their phenotype
includes a loss of adipose tissue via
increased lipolysis (39). In the atrial
myxoma studied here, haploinsufficiency of R1α combined with tumorigenesis is associated with a reversal of
the R1α:R2β ratio. These findings
remain to be confirmed in other
tumor samples as they become available. We hypothesize that haploinsufficiency of the R1α subunit in the
heart of Carney complex patients may
lead to decreased PKA activity with
consequent partial compensatory
increase in R2β expression and thereby induce adipose tissue growth in the
interatrial septum. Furthermore, additional sporadic mutation of PRKAR1α
and/or other genes in the cAMPdependent signal transduction pathway may contribute to decreased PKA
activity and altered PKA regulatory
isoform expression which, in turn,
ultimately leads to cardiac myxoma
formation. In fact, the propensity of
R2β-regulated PKA activity to induce
cellular differentiation (18) may
explain the wide variety of differentiated cell lineages (2, 3) observed within cardiac myxomas. In vitro and in
vivo experimental models that probe
PRKAR1α and other PKA regulatory
subunit expression in the heart will
elucidate PKA-dependent pathways
for cardiac cell growth and differentiation. Manipulation of such PKA-
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dependent pathways has already
prompted therapeutic modalities for
malignancies (18) and ultimately may
suggest novel therapies to prompt cardiac cell regeneration in the ischemic
and cardiomyopathic heart.
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